DalCor Pharmaceuticals today announced that the independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications.
Canada2001 Boulevard Robert Bourassa,
Suite 1700
Montreal, Quebec H3A 2A6
Tel.: +1 514-508-5099
Fax.: +1 514-564-6424
Email: [email protected]
SWITZERLANDBaarerstrasse 2 CH-6302 Zug
Tel.: +41 41 727 67 89
Email: [email protected]
UNITED KINGDOMQ3, the Square Randalls Way
Leatherhead KT22 7TW
Tel: +44 207-842-2275
Email: [email protected]
UNITED STATESYou cannot copy content of this page